Genesis Group successfully completed the amplification and clinical GMP production of a new dual-specific antibody continuity irrigation process for cancer immunotherapy.

Guide: Genesis Group announces the successful expansion of the dual-specific antibody irrigation process to 200L and has completed its clinical GMP batch production for Phase I clinical trials.
. Suzhou and Hangzhou, September 15, 2020 / Mercer Group, an international biopharmaceutical company with full process integration capabilities in biopharmaceutical research and development, clinical and production, today announced the successful expansion of the dual-specific antibody irrigation process to 200L, and has completed its clinical GMP batch production for Phase I clinical trials.
, Chief Technology Officer of the Company," said Dr. Huang Guangcheng, Chief Technology Officer of Thessun Group.
we have developed a high-yield irrigation technology platform using self-developed, chemically specific media and have successfully applied it to pipeline projects.
Based on our high yield irrigation process, a single-use bioreacter (SUB) of 200L and below can meet the clinical production needs of Phase I/II, while commercial production needs require only a 500L SUB.
" is another achievement on the irrigation platform following the announcement in February this year that the productivity of its multiple cell lineages exceeded 4 g/L/day.
Troon Group will continue to focus on integrating technological innovations such as continuous process platforms, enhancing development and production capacity, helping to accelerate the clinical process of new drugs, and further developing high-quality and affordable innovative biologics that benefit patients worldwide.
About Genesis Group Is an international biopharmaceutical company with fully integrated capabilities in biopharmaceutical research and development, clinical and production.
has successfully established a global business layout: a drug discovery, clinical and transformational research center in Suzhou, a process and product development center and pharmaceutical production base in Hangzhou, clinical development centers in Shanghai, Guangzhou, Beijing and Princeton, USA, and a foreign cooperation center in Boston, USA.
's development pipeline covers more than a dozen new drug molecules in the field of tumors and screened non-tumors.
, the company has so far financed more than $230 million.
.